Selank
Anxiolytic peptide
Research overview
A synthetic heptapeptide studied in models of anxiety, working memory and immune modulation.
Descriptions reference published research areas for laboratory context only and are not claims of efficacy, safety, or intended use in humans or animals.
- Price
- $125 CAD
- Purity
- ≥98.9% (HPLC)
- Presentation
- 10 mg lyophilized vial
Order / inquire about Selank
Email our research desk for availability, batch Certificates of Analysis, and account setup. We respond to verified research inquiries from Canada only.
Verified Canadian research inquiries only · 18+
For laboratory research use only — not for human or veterinary use
Selank is a chemical reference material sold strictly for in-vitro laboratory research by qualified professionals. It is not a drug, food, cosmetic, or natural health product; it has not been evaluated or approved by Health Canada; and it must never be ingested, injected, or applied to humans or animals. Sold in Canada only, to purchasers 18+. See our Research Use Policy.
Research encyclopedia
Everything the literature has studied.
For laboratory research use only — not for human or veterinary use. The content below summarizes published research context only. It is not medical advice, makes no therapeutic claims, and describes no intended use in humans or animals. These materials have not been evaluated or approved by Health Canada.
What it is
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) engineered as a metabolically stabilized analog of the endogenous immunomodulatory tetrapeptide tuftsin. It has been investigated as a non-sedating, non-dependence-forming anxiolytic and nootropic reference compound and is clinically registered in Russia.
Mechanism of action
Proposed allosteric modulation of GABA-A receptors (without acting at the benzodiazepine site), stabilization of enkephalins by inhibiting their enzymatic degradation, upregulation of BDNF, modulation of serotonergic tone, and normalization of the HPA axis. As a tuftsin analog it also selectively induces interferon-alpha (IFN-α) and modulates cytokine expression.
Research areas
- Generalized anxiety and neurasthenia models
- Cognitive / nootropic support
- Immunomodulation and antiviral (IFN-α) response
- Modulation of the stress response
Studied effects in research models
- Anxiolytic effect comparable to benzodiazepines without sedation (Russian trials)
- No tolerance or withdrawal reported in the available studies
- Reduction of pro-inflammatory cytokines (IL-6, IL-1β) and IFN-α induction
- BDNF upregulation in preclinical models
Effects listed describe observations reported in laboratory or animal research models only — not outcomes claimed for humans or animals.
Biomarkers tracked in related research
Discovery & background
Developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences together with the Institute of Physiologically Active Compounds. The tuftsin core was extended with a Pro-Gly-Pro C-terminal motif to resist enzymatic degradation, yielding an anxiolytic/immunomodulatory peptide subsequently registered in Russia.
Considerations & limitations
Research-use-only reference material; not approved by Health Canada, the FDA, or the EMA (registered only in Russia). Nearly all clinical research is Russian, with small samples and little independent Western replication or large blinded trials, so publication bias and limited high-impact peer review should be weighed. Pharmacokinetics and long-term safety are poorly characterized; no data in pregnancy, lactation, or pediatrics.
References
- [1]Zozulia et al., 2008 (Selank in generalized anxiety) — Zh Nevrol Psikhiatr Im S S Korsakova; 108:38-48; PMID: 18577955
- [2]Kolomin et al., 2013 (Selank gene-expression effects) — J Mol Neurosci; 51:1024-1029; PMID: 23760987
- [3]Volkova et al., 2016 (Selank BDNF review) — Front Pharmacol; 7:307; PMID: 27672365